Corcept Therapeutics (CORT) Hisse Fiyat
Corcept Therapeutics Fiyat
Gelir, son 19 yılda yıllık bileşik %51,2 artarak 761,41 M USD seviyesine ulaştı. Hisse başına kâr, son 9 yılda yıllık %31,2 büyüdü. Corcept Therapeutics şirketinde net marj %13,1 seviyesinde bulunuyor; birkaç yıl önceki %30,7 seviyesine göre geriledi. Analistler 142,50 USD medyan fiyat hedefi belirliyor; bu, güncel fiyatın %37,0 üzerinde bir seviyeye işaret ediyor. 12 analistten 10 tanesi hisse için alım öneriyor — genel konsensüs: Al.
Corcept Therapeutics hisse senedi fiyatı
Bu verilere Eulerpool API üzerinden ulaşın
Ayda 100.000 ücretsiz istek · kredi kartı yok
Corcept Therapeutics iş modeli ve hisse analizi
Corcept Therapeutics hakkında sık sorulan sorular
The business model of Corcept Therapeutics Inc. revolves around developing, manufacturing, and commercializing drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. As a pharmaceutical company, Corcept focuses on discovering innovative therapies to address unmet medical needs. With a particular emphasis on the research and development of selective cortisol modulators, the company aims to provide effective solutions for patients suffering from disorders caused by the excess production of cortisol. Corcept Therapeutics Inc. aims to improve patient outcomes by harnessing its expertise in the field of selective cortisol modulation and delivering innovative medical therapies.
Corcept Therapeutics Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Corcept Therapeutics Inc in the market are pharmaceutical companies such as Novartis, Pfizer, and Eli Lilly and Company.
Corcept Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. Founded in 1998, Corcept has its headquarters in Menlo Park, California. The company's flagship product, Korlym, is an FDA-approved medication for patients with Cushing's syndrome. Corcept's focus on cortisol-related disorders has led to the exploration of additional treatment indications. With a dedicated research and development team, Corcept Therapeutics Inc continues to innovate in the field of endocrinology and neurobiology, striving to improve patients' lives worldwide.
Corcept Therapeutics Inc has achieved significant milestones in its history. One notable achievement is the approval and commercialization of its flagship drug, Korlym, by the U.S. Food and Drug Administration (FDA). This medication is used to treat patients with Cushing's syndrome, a rare and severe endocrine disorder. Additionally, Corcept has successfully expanded the approved indications for Korlym to include the treatment of patients with hyperglycemia secondary to Cushing's syndrome. The company has also completed several clinical trials, demonstrating the efficacy and safety of its products. Overall, Corcept Therapeutics Inc has made remarkable strides in advancing the field of endocrinology with its innovative treatments.
Corcept Therapeutics Inc is primarily present in the United States.
Corcept Therapeutics Inc represents values of innovation, dedication, and patient-centric approach. As a biopharmaceutical company, Corcept is committed to developing innovative medications to improve patient lives. Their corporate philosophy revolves around the belief that patients are at the heart of what they do, and they strive to address unmet medical needs. Corcept Therapeutics Inc employs cutting-edge scientific research and partnerships to create effective therapies for serious disorders, including Cushing's syndrome. With a focus on scientific excellence, patient well-being, and dedication to improving healthcare outcomes, Corcept Therapeutics Inc stands out in the biopharmaceutical industry. Keep up with the latest developments and news regarding Corcept Therapeutics Inc on our website.
Analistler şu anda Corcept Therapeutics hissesi için ortalama 125,33 USD hedef fiyat belirliyor (medyan: 142,50 USD); bu, son fiyata göre +20,5 % anlamına gelir. Konsensüs 12 analist notuna dayanır.
12 analist şu anda Corcept Therapeutics hissesini değerlendiriyor: 10 al, 1 tut, 1 sat öneriyor. 2026 için analistler Corcept Therapeutics şirketinin 1,11 Md USD gelir ve 2,04 USD hisse başına kâr üretmesini bekliyor.
Güncel döviz kuruyla Corcept Therapeutics hissesi 92,89 EUR (104,05 USD) seviyesindedir.
Corcept Therapeutics hissesi (CORT) 7 borsada işlem görür, bunlar arasında: NASDAQ (CORT), London (0I3Q.L), SIX (Zürich) (HTD.SW), Frankfurt (HTD.F), München (HTD.MU), Düsseldorf (HTD.DU).
Corcept Therapeutics Inc is a pharmaceutical company focused on the development of medications to treat serious diseases such as Cushing's syndrome and solid tumors. The company operates in three business segments: (1) medication development and commercialization, (2) clinical studies, and (3) licensing fees from third-party companies. Corcept develops medications that block cortisol receptors, such as Korlym for treating Cushing's syndrome. They also conduct clinical studies to further develop and prove the efficacy of their medications. Additionally, the company generates revenue through licensing agreements with third-party companies. Corcept has established partnerships with IBSA Pharma and Teva Pharmaceutical Industries to market Korlym in Europe and Israel. Overall, Corcept focuses on addressing medical challenges, aligning its business segments, and advancing the clinical development of its products. It has become a leading company in this field through its specialization in a specific disease and the development of drugs to treat it. Collaborations and a strong focus on clinical research have contributed to Corcept's sustainable business model aimed at long-term growth and success in improving healthcare. The company's wide range of products is tailored to its core competencies and supports its comprehensive healthcare model.
beklenen'nin Corcept Therapeutics hasılatı 1,11 Md USD'dir. Bu rakam, mevcut finansal verilere dayanmakta ve şirketin iş performansını yansıtmaktadır.
beklenen'nin Corcept Therapeutics karı 244,24 M USD'dir. Net kar, tüm giderleri düştükten sonra şirketin kârlılığını gösterir.
Corcept Therapeutics'nin Fiyat/Kazanç (F/K) oranı şu anda 51,06'dir. F/K oranı, cari hisse fiyatını hisse başına kazançla karşılaştırır ve yatırımcıların Corcept Therapeutics hisse senedinin değerlemesini değerlendirmelerine yardımcı olur.
Corcept Therapeutics'nin Fiyat/Satış (F/S) oranı şu anda 11,22'dir. F/S oranı, pazar kapitalizasyonunu yıllık gelirle karşılaştırır ve Corcept Therapeutics hisse senedinin değerleme metriği olarak hizmet eder.
Corcept Therapeutics'nin Eulerpool Kalite Puanı 6/10'dur.
Corcept Therapeutics'nin ISIN'i US2183521028'dir. ISIN (Uluslararası Menkul Kıymetler Kimlik Numarası), menkul kıymetler için küresel olarak benzersiz bir tanımlayıcıdır.
Corcept Therapeutics'nin WKN'i 529882'dir. WKN (Wertpapierkennnummer), menkul kıymetleri tanımlamak için kullanılan altı haneli bir Alman kimlik numarasıdır.
Corcept Therapeutics'nin ticker'ı CORT'dir. Ticker sembolü, Corcept Therapeutics hisseleri borsada işlem görmek için kullanılır.
Corcept Therapeutics Hissesi
Corcept Therapeutics Emsaller Grubu
Corcept Therapeutics Ticker
Corcept Therapeutics FIGI
Corcept Therapeutics'nin tüm temel göstergeleri ve derinlemesine analizi
Corcept Therapeutics hissesine yönelik aktienanalizimiz, satış, kar, P/E oranı, P/S oranı, EBIT gibi önemli mali kriterleri içermekte olup, dividende bilgilerini de ele almaktadır. Ayrıca, hisseler, piyasa değeri, borçlar, özsermaye ve Corcept Therapeutics şirketin yükümlülükleri gibi konuları incelemekteyiz. Bu konular hakkında daha detaylı bilgilere ihtiyacınız varsa, web sitemizin alt sayfalarında kapsamlı analizler sunuyoruz: